LYNPARZA® (olaparib) Approved in the EU for Use as First-Line Maintenance Therapy in Patients With BRCA-Mutated Advanced Ovarian Cancer

60

KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–LYNPARZA® (olaparib) Approved in the EU for Use as First-Line Maintenance Therapy in Patients With BRCA-Mutated Advanced Ovarian Cancer….

 

http://www.businesswire.com/news/home/20190618005123/en/LYNPARZA%C2%AE-olaparib-Approved-EU-First-Line-Maintenance-Therapy/

- Advertisement -